Ascidian Therapeutics
Boston, United States · Biotechnology, Health Care, Medical
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders,
Key facts
- Headquarters
- Boston, United States
- Employees
- 34
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- ascidian-tx.com
- Company page
Recent activity at Ascidian Therapeutics
- : Ascidian Therapeutics Appoints Daniel Rosan as President
- : Ascidian and Eli Lilly enter a partnership worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases.
- : Ascidian Therapeutics and Forge Biologics Forge Partnership to Enhance RNA Editing Therapy for Stargardt Disease.
- : Ascidian Therapeutics Appoints Murray A. Abramson as Chief Development Officer
- : Ascidian Therapeutics Raises $40 Million In Series A Extension Financing From Apple Tree Partners And Appoints Michael Ehlers As Interim Ceo
- : Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer
Ascidian Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2023 | Series A | $40.0M |
Leadership
- Daniel Rosan, President
- Murray A. Abramson, Chief Development Officer
Verified email and direct lines for Ascidian Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Ascidian Therapeutics in the news
- Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs - Reuters (Jun 03, 2026)
- Lilly, Ascidian Strike RNA-Editing Pact For Up to $1.9 Billion - Bloomberg.com (Jun 03, 2026)
- Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO - PR Newswire (Nov 08, 2023)
- Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech (Dec 17, 2025)
Companies similar to Ascidian Therapeutics
- n-Lorem Foundation · Biotechnology, Health Care, Medical, Therapeutics
- Aptose Biosciences · Biotechnology, Health Care, Medical, Therapeutics
- Ellipses Pharma Limited · Biotechnology, Health Care, Medical, Therapeutics
- Georgiamune · Biotechnology, Health Care, Medical, Therapeutics
- NeuroKaire · Biotechnology, Health Care, Medical, Therapeutics
About Ascidian Therapeutics: questions and answers
What does Ascidian Therapeutics do?
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders,
Where is Ascidian Therapeutics headquartered?
Ascidian Therapeutics is headquartered in Boston, United States.
How many employees does Ascidian Therapeutics have?
Ascidian Therapeutics has about 34 employees.
Has Ascidian Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Ascidian Therapeutics. The most recent, Series A of $40.0M, was in Nov 2023.
Who leads Ascidian Therapeutics?
Daniel Rosan is a President at Ascidian Therapeutics.
What is the latest news on Ascidian Therapeutics?
On Jul 21, 2026, Ascidian Therapeutics Appoints Daniel Rosan as President
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy